 |
|
Genetic predisposition in nonalcoholic fatty liver disease
Silvia Sookoian, Carlos J. Pirola
Clin Mol Hepatol. 2017;23(1):1-12. Published online 2017 Mar 9 DOI: https://doi.org/10.3350/cmh.2016.0109
|
|
Citations to this article as recorded by
 Navigating nonalcoholic fatty liver disease (NAFLD): Exploring the roles of estrogens, pharmacological and medical interventions, and life style
Qianying Zuo, Nicole Hwajin Park, Jenna Kathryn Lee, Ashlie Santaliz-Casiano, Zeynep Madak-Erdogan
Steroids.2024; 203: 109330. CrossRef Liver fibrosis in NAFLD/NASH: from pathophysiology towards diagnostic and therapeutic strategies
Maurizio Parola, Massimo Pinzani
Molecular Aspects of Medicine.2024; 95: 101231. CrossRef The pathophysiology of MASLD: an immunometabolic perspective
Julian Schwärzler, Felix Grabherr, Christoph Grander, Timon E. Adolph, Herbert Tilg
Expert Review of Clinical Immunology.2024; 20(4): 375. CrossRef Whole-Exome Sequencing (WES) Reveals Novel Sex-Specific Gene Variants in Non-Alcoholic Steatohepatitis (MASH)
Jing Wei, Boyang Jason Wu, Sayed S. Daoud
Genes.2024; 15(3): 357. CrossRef Genetic and Metabolic Characteristics of Lean Nonalcoholic Fatty Liver Disease in a Korean Health Examinee Cohort
Huiyul Park, Eileen L. Yoon, Goh Eun Chung, Eun Kyung Choe, Jung Ho Bae, Seung Ho Choi, Mimi Kim, Woochang Hwang, Hye-Lin Kim, Sun Young Yang, Dae Won Jun
Gut and Liver.2024; 18(2): 316. CrossRef Relevance of PNPLA3, TM6SF2, HSD17B13, and GCKR Variants to MASLD Severity in an Egyptian Population
Nehal Elmansoury, Ahmed A. Megahed, Ahmed Kamal, Nefertiti El-Nikhely, Marina Labane, Manal Abdelmageed, Ann K. Daly, Ahmed Wahid
Genes.2024; 15(4): 455. CrossRef Probiotics—A Promising Novel Therapeutic Approach in the Management of Chronic Liver Diseases
Gokulapriya Ramachandran, Biju Pottakkat
Journal of Medicinal Food.2024;[Epub] CrossRef Review: Opportunities and barriers for omics-based biomarker discovery in steatotic liver diseases
Maja Thiele, Ida Falk Villesen, Lili Niu, Stine Johansen, Karolina Sulek, Suguru Nishijima, Lore Van Espen, Marisa Keller, Mads Israelsen, Tommi Suvitaival, Andressa de Zawadzki, Helene Bæk Juel, Maximilian Joseph Brol, Sara Elisabeth Stinson, Yun Huang,
Journal of Hepatology.2024;[Epub] CrossRef Advances in our understanding of the molecular heterogeneity of fatty liver disease: towards informed treatment decision making
Carlos J Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2023;[Epub] CrossRef Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2023; 29(Suppl): S184. CrossRef The association of non‐alcoholic fatty liver disease between parents and adolescent children
Yewan Park, Dong Hyun Sinn, Kyunga Kim, Geum‐Youn Gwak
Alimentary Pharmacology & Therapeutics.2023; 57(2): 245. CrossRef Editorial: ‘Talis pater, talis filius’
Natalia Rosso, Claudio Tiribelli
Alimentary Pharmacology & Therapeutics.2023; 57(1): 171. CrossRef NAFLD and nutraceuticals: a review of completed phase III and IV clinical trials
Omar E. Hegazi, Samer O. Alalalmeh, Ghala Rashid Humaid Alnuaimi, Moyad Shahwan, Ammar Abdulrahman Jairoun, Nasser M. Alorfi, Shaker A. Majrashi, Mustfa Faisal Alkhanani, Abdullah Alkhattabi, Mansour M. Alourfi, Faris A. Alsolami, Saeed Alsharif, Hatim Al
Frontiers in Medicine.2023;[Epub] CrossRef Using epigenomics to understand cellular responses to environmental influences in diseases
Julia J. Wattacheril, Srilakshmi Raj, David A. Knowles, John M. Greally, Gregory P. Copenhaver
PLOS Genetics.2023; 19(1): e1010567. CrossRef Understanding NAFLD: From Case Identification to Interventions, Outcomes, and Future Perspectives
Daniel Clayton-Chubb, William Kemp, Ammar Majeed, John S. Lubel, Alex Hodge, Stuart K. Roberts
Nutrients.2023; 15(3): 687. CrossRef Lack of GPR180 ameliorates hepatic lipid depot via downregulation of mTORC1 signaling
Ken Yoshida, Kazuha Yokota, Kazuhisa Watanabe, Hidetoshi Tsuda, Ayumi Matsumoto, Hiroaki Mizukami, Sadahiko Iwamoto
Scientific Reports.2023;[Epub] CrossRef TM6SF2-rs58542926 Genetic Variant Modifies the Protective Effect of a “Prudent” Dietary Pattern on Serum Triglyceride Levels
Ioanna Panagiota Kalafati, Maria Dimitriou, Konstantinos Revenas, Alexander Kokkinos, Panos Deloukas, George V. Dedoussis
Nutrients.2023; 15(5): 1112. CrossRef Role of immune responses in the development of NAFLD-associated liver cancer and prospects for therapeutic modulation
Neda Yahoo, Michael Dudek, Percy Knolle, Mathias Heikenwälder
Journal of Hepatology.2023; 79(2): 538. CrossRef Genetic Markers Predisposing to Nonalcoholic Steatohepatitis
Aalam Sohal, Hunza Chaudhry, Kris V. Kowdley
Clinics in Liver Disease.2023; 27(2): 333. CrossRef The potential of integrating human and mouse discovery platforms to advance our understanding of cardiometabolic diseases
Aaron W Jurrjens, Marcus M Seldin, Corey Giles, Peter J Meikle, Brian G Drew, Anna C Calkin
eLife.2023;[Epub] CrossRef Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Michael H. Le, David M. Le, Thomas C. Baez, Yuankai Wu, Takanori Ito, Eunice Y. Lee, KeeSeok Lee, Christopher D. Stave, Linda Henry, Scott D. Barnett, Ramsey Cheung, Mindie H. Nguyen
Journal of Hepatology.2023; 79(2): 287. CrossRef Diversitätsfaktoren in der Gastroenterologie
Teresa Hof, Robert Thimme, Peter Hasselblatt
DMW - Deutsche Medizinische Wochenschrift.2023; 148(09): 519. CrossRef A Review of the Effects of Fucoxanthin on NAFLD
Nor Hafiza Sayuti, Khairul Najmi Muhammad Nawawi, Jo Aan Goon, Norfilza Mohd Mokhtar, Suzana Makpol, Jen Kit Tan
Nutrients.2023; 15(8): 1954. CrossRef Blood lactate levels are associated with an increased risk of metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study
Yi-Lin Ma, Jiang-Feng Ke, Jun-Wei Wang, Yu-Jie Wang, Man-Rong Xu, Lian-Xi Li
Frontiers in Endocrinology.2023;[Epub] CrossRef High fat in blood and body and increased risk of clinically diagnosed non-alcoholic fatty liver disease in 105,981 individuals
Lærke Kristine Kyhl, Børge Grønne Nordestgaard, Anne Tybjærg-Hansen, Sune Fallgaard Nielsen
Atherosclerosis.2023; 376: 1. CrossRef Cross-tissue omics analysis discovers ten adipose genes encoding secreted proteins in obesity-related non-alcoholic fatty liver disease
Nicholas Darci-Maher, Marcus Alvarez, Uma Thanigai Arasu, Ilakya Selvarajan, Seung Hyuk T. Lee, David Z. Pan, Zong Miao, Sankha Subhra Das, Dorota Kaminska, Tiit Örd, Jihane N. Benhammou, Martin Wabitsch, Joseph R. Pisegna, Ville Männistö, Kirsi H. Pietil
eBioMedicine.2023; 92: 104620. CrossRef Type 2 Diabetes Mellitus, Non-Alcoholic Fatty Liver Disease, and Metabolic Repercussions: The Vicious Cycle and Its Interplay with Inflammation
Rafał Frankowski, Mateusz Kobierecki, Andrzej Wittczak, Monika Różycka-Kosmalska, Tadeusz Pietras, Kasper Sipowicz, Marcin Kosmalski
International Journal of Molecular Sciences.2023; 24(11): 9677. CrossRef Effects of gut microbial therapy on lipid profile in individuals with non-alcoholic fatty liver disease: an umbrella meta-analysis study
Amirhossein Naghipour, Ehsan Amini-Salehi, Mahdi Orang Gorabzarmakhi, Milad Shahdkar, Bahman Fouladi, Iraj Alipourfard, Zahra Momayez Sanat
Systematic Reviews.2023;[Epub] CrossRef Prospects of evolution-based artificial intelligence models in genome-wide studies to stratify genetic risk variants in nonalcoholic fatty liver disease
Helen Huang, Wireko A. Awuah, Tulika Garg, Jyi Cheng Ng, Aashna Mehta, Krishna Ramamoorthy, Jacob Kalmanovich, Mohammad M. Hasan
Annals of Medicine & Surgery.2023; 85(6): 2743. CrossRef Genetic and metabolic aspects of non-alcoholic fatty liver disease (NAFLD) pathogenicity
Saumya Madushani Samarasinghe, Asanka Sudeshini Hewage, Rohan Chaminda Siriwardana, Kamani Hemamala Tennekoon, Madunil Anuk Niriella, Sumadee De Silva
Egyptian Journal of Medical Human Genetics.2023;[Epub] CrossRef Role of Matrix Gla Protein in Transforming Growth Factor-β Signaling and Nonalcoholic Steatohepatitis in Mice
Simon T. Hui, Lili Gong, Chantle Swichkow, Montgomery Blencowe, Dorota Kaminska, Graciel Diamante, Calvin Pan, Meet Dalsania, Samuel W. French, Clara E. Magyar, Päivi Pajukanta, Jussi Pihlajamäki, Kristina I. Boström, Xia Yang, Aldons J. Lusis
Cellular and Molecular Gastroenterology and Hepatology.2023; 16(6): 943. CrossRef Usefulness of PNPLA3 variant for predicting hepatic events in steatotic liver disease: a matter of ethnicity or baseline risk?
Umberto Vespasiani‐Gentilucci, Luca Valenti, Stefano Romeo
Liver International.2023; 43(10): 2052. CrossRef New horizons of human genetics in digestive diseases
Lanlan Chen, Guoyue Lv
eGastroenterology.2023; 1(2): e100029. CrossRef Microbiome and Genetic Factors in the Pathogenesis of Liver Diseases
Dimitrina Miteva, Monika Peshevska-Sekulovska, Violeta Snegarova, Milena Peruhova, Georgi H. Vasilev, Georgi V. Vasilev, Metodija Sekulovski, Snezhina Lazova, Milena Gulinac, Latchezar Tomov, Antoaneta Mihova, Tsvetelina Velikova
Gastroenterology Insights.2023; 14(4): 575. CrossRef Epigenetics factors in nonalcoholic fatty liver disease
Carlos Jose Pirola, Silvia Sookoian
Expert Review of Gastroenterology & Hepatology.2022; 16(6): 521. CrossRef Effects of PNPLA3, TM6SF2 and SAMM50 on the development and severity of non‐alcoholic fatty liver disease in children
Kyung Jae Lee, Jin Soo Moon, Nan Young Kim, Jae Sung Ko
Pediatric Obesity.2022;[Epub] CrossRef A Polygenic Risk Score to Refine Risk Stratification and Prediction for Severe Liver Disease by Clinical Fibrosis Scores
Antonio De Vincentis, Federica Tavaglione, Oveis Jamialahmadi, Antonio Picardi, Raffaele Antonelli Incalzi, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci
Clinical Gastroenterology and Hepatology.2022; 20(3): 658. CrossRef Metabolic and genetic determinants for progression to severe liver disease in subjects with obesity from the UK Biobank
Antonio De Vincentis, Federica Tavaglione, Rocco Spagnuolo, Roberta Pujia, Dario Tuccinardi, Gianluca Mascianà, Antonio Picardi, Raffaele Antonelli Incalzi, Luca Valenti, Stefano Romeo, Umberto Vespasiani-Gentilucci
International Journal of Obesity.2022; 46(3): 486. CrossRef Genome‐Wide Association Study of NAFLD Using Electronic Health Records
Cameron J. Fairfield, Thomas M. Drake, Riinu Pius, Andrew D. Bretherick, Archie Campbell, David W. Clark, Jonathan A. Fallowfield, Caroline Hayward, Neil C. Henderson, Peter K. Joshi, Nicholas L. Mills, David J. Porteous, Prakash Ramachandran, Robert K. S
Hepatology Communications.2022; 6(2): 297. CrossRef Prevalence and Predictors of Nonalcoholic Fatty Liver Disease in Family Members of Patients With Nonalcoholic Fatty Liver Disease
Abhinav Anand, Amit A. Singh, Anshuman Elhence, Manas Vaishnav, Sagnik Biswas, Deepak Gunjan, Shivanand R. Gamanagatti, Baibaswata Nayak, Ramesh Kumar, Shalimar
Journal of Clinical and Experimental Hepatology.2022; 12(2): 362. CrossRef Association of UCP3 Polymorphisms with Nonalcoholic Steatohepatitis and Metabolic Syndrome in Nonalcoholic Fatty Liver Disease Brazilian Patients
Karla Sawada Toda-Oti, José Tadeu Stefano, Ana Mercedes Cavaleiro, Flair José Carrilho, Maria Lúcia Correa-Gianella, Cláudia Pinto Marques de Souza de Oliveira
Metabolic Syndrome and Related Disorders.2022; 20(2): 114. CrossRef Metabolism and Health Effects of Rare Sugars in a CACO-2/HepG2 Coculture Model
Amar van Laar, Charlotte Grootaert, Filip Van Nieuwerburgh, Dieter Deforce, Tom Desmet, Koen Beerens, John Van Camp
Nutrients.2022; 14(3): 611. CrossRef Early Diagnosis of Non-Alcoholic Steatohepatitis in Patients with Non-Alcoholic Fatty Liver Disease
露文 李
Advances in Clinical Medicine.2022; 12(02): 986. CrossRef Epidemiological and Genetic Aspects of NAFLD and NASH in Mexico
Paulina Vidal‐Cevallos, Aldo Torre, Nahum Mendez‐Sanchez, Misael Uribe, Norberto C. Chavez‐Tapia
Clinical Liver Disease.2022; 19(2): 68. CrossRef The association between rs1260326 with the risk of NAFLD and the mediation effect of triglyceride on NAFLD in the elderly Chinese Han population
Fan Yuan, Zhan Gu, Yan Bi, Ruixue Yuan, Weibo Niu, Decheng Ren, Lei Zhang, Guang He, Bao-Cheng Liu
Aging.2022; 14(6): 2736. CrossRef Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)
Laura Valenzuela-Vallejo, Christos S. Mantzoros
Metabolism.2022; 134: 155246. CrossRef Mitochondrial Dysfunction Plays Central Role in Nonalcoholic Fatty Liver Disease
Raghu Ramanathan, Ahmad Hassan Ali, Jamal A. Ibdah
International Journal of Molecular Sciences.2022; 23(13): 7280. CrossRef African genetic ancestry is associated with lower frequency of PNPLA3 G allele in non-alcoholic fatty liver in an admixed population
Lourianne Nascimento Cavalcante, Jun Porto, Daniel Mazo, Adhemar Longatto-Filho, José Tadeu Stefano, Andre Castro Lyra, Flair Jose Carrilho, Rui Manuel Reis, Venâncio A.F. Alves, Arun J. Sanyal, Claudia P Oliveira
Annals of Hepatology.2022; 27(6): 100728. CrossRef A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation
Marijana Vujkovic, Shweta Ramdas, Kim M. Lorenz, Xiuqing Guo, Rebecca Darlay, Heather J. Cordell, Jing He, Yevgeniy Gindin, Chuhan Chung, Robert P. Myers, Carolin V. Schneider, Joseph Park, Kyung Min Lee, Marina Serper, Rotonya M. Carr, David E. Kaplan, M
Nature Genetics.2022; 54(6): 761. CrossRef The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
Magdalena Rausch, Sophia L. Samodelov, Michele Visentin, Gerd A. Kullak-Ublick
International Journal of Molecular Sciences.2022; 23(22): 13967. CrossRef Multifaceted Clinical Research on Obesity-related Disease Prevention Focusing on the DsbA-L Gene
Kentaro Oniki
YAKUGAKU ZASSHI.2022; 142(11): 1177. CrossRef Non-alcoholic fatty liver disease (NAFLD) and mental illness: Mechanisms linking mood, metabolism and medicines
Anwesha Gangopadhyay, Radwa Ibrahim, Karli Theberge, Meghan May, Karen L. Houseknecht
Frontiers in Neuroscience.2022;[Epub] CrossRef Utility of Human Relevant Preclinical Animal Models in Navigating NAFLD to MAFLD Paradigm
Damien Chua, Zun Siong Low, Guo Xiang Cheam, Aik Seng Ng, Nguan Soon Tan
International Journal of Molecular Sciences.2022; 23(23): 14762. CrossRef Race and Ethnicity in Non-Alcoholic Fatty Liver Disease (NAFLD): A Narrative Review
Kiarash Riazi, Mark G. Swain, Stephen E. Congly, Gilaad G. Kaplan, Abdel-Aziz Shaheen
Nutrients.2022; 14(21): 4556. CrossRef Comprehensive analysis of the translatome reveals the relationship between the translational and transcriptional control in high fat diet-induced liver steatosis
Zupeng Luo, Hailong Hu, Siqi Liu, Zhiwang Zhang, Yixing Li, Lei Zhou
RNA Biology.2021; 18(6): 863. CrossRef The gut mycobiome: a novel player in chronic liver diseases
Lu Jiang, Peter Stärkel, Jian-Gao Fan, Derrick Eugene Fouts, Petra Bacher, Bernd Schnabl
Journal of Gastroenterology.2021; 56(1): 1. CrossRef Flavin Adenine Dinucleotide Depletion Caused by electron transfer flavoprotein subunit alpha Haploinsufficiency Leads to Hepatic Steatosis and Injury in Zebrafish
Ki‐Hoon Park, Monika Gooz, Zhi‐Wei Ye, Jie Zhang, Gyda C. Beeson, Don C. Rockey, Seok‐Hyung Kim
Hepatology Communications.2021; 5(6): 976. CrossRef Defining NASH from a Multi-Omics Systems Biology Perspective
Lili Niu, Karolina Sulek, Catherine G. Vasilopoulou, Alberto Santos, Nicolai J. Wewer Albrechtsen, Simon Rasmussen, Florian Meier, Matthias Mann
Journal of Clinical Medicine.2021; 10(20): 4673. CrossRef Changes in liver steatosis in HIV-positive women are associated with the BMI, but not with biomarkers
Rafael Fernandez-Botran, Michael W. Plankey, Deanna Ware, José Bordon
Cytokine.2021; 144: 155573. CrossRef Human Genetics to Identify Therapeutic Targets for NAFLD: Challenges and Opportunities
Xiaomi Du, Natalie DeForest, Amit R. Majithia
Frontiers in Endocrinology.2021;[Epub] CrossRef Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
Clinical and Molecular Hepatology.2021; 27(3): 486. CrossRef Genetic risk scores and personalization of care in fatty liver disease
Cristiana Bianco, Federica Tavaglione, Stefano Romeo, Luca Valenti
Current Opinion in Pharmacology.2021; 61: 6. CrossRef Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients
David Sooik Kim, Soo Young Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Kwang-Hyub Han, Yu Rim Lee, Won Young Tak, Young Oh Kweon, Inkyung Jung, Minkyung Han, Eun Hwa Kim, Sang Hoon Ahn, Seung Up Kim
Journal of Korean Medical Science.2021;[Epub] CrossRef Disease-specific eQTL screening reveals an anti-fibrotic effect of AGXT2 in non-alcoholic fatty liver disease
Taekyeong Yoo, Sae Kyung Joo, Hyo Jung Kim, Hyun Young Kim, Hyungtai Sim, Jieun Lee, Hee-Hoon Kim, Sunhee Jung, Youngha Lee, Oveis Jamialahmadi, Stefano Romeo, Won-Il Jeong, Geum-Sook Hwang, Keon Wook Kang, Jae Woo Kim, Won Kim, Murim Choi
Journal of Hepatology.2021; 75(3): 514. CrossRef The effects of guluronic acid (G2013), a new emerging treatment, on inflammatory factors in nonalcoholic steatohepatitis patients under in vitro conditions
Safa Tahmasebi, Hassan Neishaboori, Davood Jafari, Elham Faghihzadeh, Abdolreza Esmaeilzadeh, Abbas Mirshafiey
Immunopharmacology and Immunotoxicology.2021; 43(5): 562. CrossRef Contribution of Metabolomics to the Understanding of NAFLD and NASH Syndromes: A Systematic Review
Cristina Piras, Antonio Noto, Luciano Ibba, Martino Deidda, Vassilios Fanos, Sandro Muntoni, Vera Piera Leoni, Luigi Atzori
Metabolites.2021; 11(10): 694. CrossRef Sirtuin3 rs28365927 functional variant confers to the high risk of non-alcoholic fatty liver disease in Chinese Han population
Li-jie Chen, Jing Guo, Song-xia Zhang, Ying Xu, Qing Zhao, Wei Zhang, Jian Xiao, Yao Chen
Lipids in Health and Disease.2021;[Epub] CrossRef Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
João V. S. Guerra, Marieli M. G. Dias, Anna J. V. C. Brilhante, Maiara F. Terra, Marta García-Arévalo, Ana Carolina M. Figueira
Nutrients.2021; 13(8): 2830. CrossRef Lipid nanoparticle formulations for targeting leukocytes with therapeutic RNA in liver fibrosis
Matthias Bartneck
Advanced Drug Delivery Reviews.2021; 173: 70. CrossRef Factors That Predict the Progression of Non-alcoholic Fatty Liver Disease (NAFLD)
Madhangi Parameswaran, Hamzah A Hasan, Jafor Sadeque, Sharan Jhaveri, Chaithanya Avanthika, Abimbola E Arisoyin, Maulik B Dhanani, Swaroopa M Rath
Cureus.2021;[Epub] CrossRef Racial differences in prevalence and severity of non-alcoholic fatty liver disease
Maurizio Bonacini, Farah Kassamali, Swathi Kari, Nieves Lopez Barrera, Mohamed Kohla
World Journal of Hepatology.2021; 13(7): 763. CrossRef Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease
Dong Hyun Sinn, Danbee Kang, Soo Jin Cho, Seung Woon Paik, Eliseo Guallar, Juhee Cho, Geum-Youn Gwak
European Journal of Gastroenterology & Hepatology.2021; 33(1S): e529. CrossRef Non‐alcoholic fatty liver disease and the incidence of myocardial infarction: A cohort study
Dong Hyun Sinn, Danbee Kang, Yoosoo Chang, Seungho Ryu, Soo Jin Cho, Seung Woon Paik, Young Bin Song, Roberto Pastor‐Barriuso, Eliseo Guallar, Juhee Cho, Geum‐Youn Gwak
Journal of Gastroenterology and Hepatology.2020; 35(5): 833. CrossRef Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology
Mohammed Eslam, Jacob George
Nature Reviews Gastroenterology & Hepatology.2020; 17(1): 40. CrossRef Correlation of the grade of hepatic steatosis between controlled attenuation parameter and ultrasound in patients with fatty liver: a multi-center retrospective cohort study
Jeong-Ju Yoo, Yang Jae Yoo, Woo Ram Moon, Seung Up Kim, Soung Won Jeong, Ha Na Park, Min Gyu Park, Jae Young Jang, Su Yeon Park, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Jong
The Korean Journal of Internal Medicine.2020; 35(6): 1346. CrossRef Fructose-mediated effects on gene expression and epigenetic mechanisms associated with NAFLD pathogenesis
Johanna K. DiStefano
Cellular and Molecular Life Sciences.2020; 77(11): 2079. CrossRef Evolution of NAFLD and Its Management
Manpreet S. Mundi, Saketh Velapati, Janki Patel, Todd A. Kellogg, Barham K. Abu Dayyeh, Ryan T. Hurt
Nutrition in Clinical Practice.2020; 35(1): 72. CrossRef Liver involvement in patients with Gaucher disease types I and III
Rodrigo Tzovenos Starosta, Filippo Pinto e Vairo, Alícia Dorneles Dornelles, Suélen Porto Basgalupp, Marina Siebert, Maria Lúcia Alves Pedroso, Carlos Thadeu Schmidt Cerski, Mário Reis Álvares-da-Silva, Ida Vanessa Doederlein Schwartz
Molecular Genetics and Metabolism Reports.2020; 22: 100564. CrossRef NETGE-PLUS: Standard and Network-Based Gene Enrichment Analysis in Human and Model Organisms
Samuele Bovo, Pier Luigi Martelli, Pietro Di Lena, Rita Casadio
Journal of Proteome Research.2020; 19(7): 2873. CrossRef Complications, morbidity and mortality of nonalcoholic fatty liver disease
Alessandro Mantovani, Eleonora Scorletti, Antonella Mosca, Anna Alisi, Christopher D. Byrne, Giovanni Targher
Metabolism.2020; 111: 154170. CrossRef Genetic Risk for Hepatic Fat among an Ethnically Diverse Cohort of Youth: The Exploring Perinatal Outcomes among Children Study
Maggie A. Stanislawski, Jessica Shaw, Elizabeth Litkowski, Ethan M. Lange, Wei Perng, Dana Dabelea, Leslie A. Lange
The Journal of Pediatrics.2020; 220: 146. CrossRef Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population
Aynur Unalp‐Arida, Constance E. Ruhl
Hepatology.2020; 71(3): 820. CrossRef Does limited expression of toll-like receptor 9 actually contribute to T cell activation and liver damage in nonalcoholic steatohepatitis?
Hyuk Soo Eun
Clinical and Molecular Hepatology.2020; 26(2): 236. CrossRef MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease
Mohammed Eslam, Arun J. Sanyal, Jacob George, Arun Sanyal, Brent Neuschwander-Tetri, Claudio Tiribelli, David E. Kleiner, Elizabeth Brunt, Elisabetta Bugianesi, Hannele Yki-Järvinen, Henning Grønbæk, Helena Cortez-Pinto, Jacob George, Jiangao Fan, Luca Va
Gastroenterology.2020; 158(7): 1999. CrossRef Human Liver Spheroids as a Model to Study Aetiology and Treatment of Hepatic Fibrosis
Tracey Hurrell, Vlasia Kastrinou-Lampou, Achilleas Fardellas, Delilah F. G. Hendriks, Åsa Nordling, Inger Johansson, Audrey Baze, Céline Parmentier, Lysiane Richert, Magnus Ingelman-Sundberg
Cells.2020; 9(4): 964. CrossRef Genome‐Wide Association Study of Lean Nonalcoholic Fatty Liver Disease Suggests Human Leukocyte Antigen as a Novel Candidate Locus
Ken Yoshida, Kazuha Yokota, Yukinobu Kutsuwada, Kazuhiro Nakayama, Kazuhisa Watanabe, Ayumi Matsumoto, Hiroshi Miyashita, Seik‐soon Khor, Katsushi Tokunaga, Yosuke Kawai, Masao Nagasaki, Sadahiko Iwamoto
Hepatology Communications.2020; 4(8): 1124. CrossRef Genome‐Wide Association Study of Liver Fat: The Multiethnic Cohort Adiposity Phenotype Study
S. Lani Park, Yuqing Li, Xin Sheng, Victor Hom, Lucy Xia, Kechen Zhao, Loreall Pooler, V. Wendy Setiawan, Unhee Lim, Kristine R. Monroe, Lynne R. Wilkens, Bruce S. Kristal, Johanna W. Lampe, Meredith Hullar, John Shepherd, Lenora L. M. Loo, Thomas Ernst,
Hepatology Communications.2020; 4(8): 1112. CrossRef Non-alcoholic fatty liver disease in inflammatory bowel disease patients
Katerina Karaivazoglou, Christos Konstantakis, Evanthia Tourkochristou, Stelios F. Assimakopoulos, Christos Triantos
European Journal of Gastroenterology & Hepatology.2020; 32(8): 903. CrossRef Insights Into Extracellular Vesicles as Biomarker of NAFLD Pathogenesis
Irma Garcia-Martinez, Rosa Alen, Patricia Rada, Angela M. Valverde
Frontiers in Medicine.2020;[Epub] CrossRef Triose Kinase Controls the Lipogenic Potential of Fructose and Dietary Tolerance
Lei Liu, Tian Li, Yilie Liao, Yalong Wang, Yang Gao, Haikun Hu, Haipeng Huang, Fang Wu, Ye-Guang Chen, Shuhua Xu, Suneng Fu
Cell Metabolism.2020; 32(4): 605. CrossRef Noncoding RNAs in Nonalcoholic Fatty Liver Disease: Potential Diagnosis and Prognosis Biomarkers
Olfa Khalifa, Khaoula Errafii, Nayla S. Al-Akl, Abdelilah Arredouani
Disease Markers.2020; 2020: 1. CrossRef Nonalcoholic Fatty Liver Disease (NAFLD) and Hepatic Cytochrome P450 (CYP) Enzymes
Rohitash Jamwal, Benjamin J. Barlock
Pharmaceuticals.2020; 13(9): 222. CrossRef Non‐alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management
Tony (Dazhong) Huang, Jason Behary, Amany Zekry
Internal Medicine Journal.2020; 50(9): 1038. CrossRef Precision medicine in nonalcoholic fatty liver disease: New therapeutic insights from genetics and systems biology
Silvia Sookoian, Carlos J. Pirola
Clinical and Molecular Hepatology.2020; 26(4): 461. CrossRef The association of genetic polymorphisms with nonalcoholic fatty liver disease in a longitudinal study
Goh Eun Chung, Eunsoon Shin, Min-Sun Kwak, Jong In Yang, Jong-Eun Lee, Eun Kyung Choe, Jeong Yoon Yim
BMC Gastroenterology.2020;[Epub] CrossRef Diversity in NAFLD: A Review of Manifestations of Nonalcoholic Fatty Liver Disease in Different Ethnicities Globally
Ma Ai Thanda Han, Qi Yu, Zaid Tafesh, Nikolaos Pyrsopoulos
Journal of Clinical and Translational Hepatology.2020; 000(000): 1. CrossRef Lifestyle and silymarin: a fight against liver damage in NAFLD associated - prediabetic disease
Cosimo Colletta, Alessandro Colletta, Giuseppe Placentino
Journal of Diabetes & Metabolic Disorders.2020; 19(2): 883. CrossRef Are Probiotics Effective in Targeting Alcoholic Liver Diseases?
Meegun Hong, Dae Hee Han, Jitaek Hong, Dong Joon Kim, Ki Tae Suk
Probiotics and Antimicrobial Proteins.2019; 11(2): 335. CrossRef Clinical and metabolic characterization of obese subjects without non-alcoholic fatty liver: A targeted metabolomics approach
A. Feldman, S.K. Eder, T.K. Felder, B. Paulweber, S. Zandanell, L. Stechemesser, M. Schranz, G. Strebinger, U. Huber-Schönauer, D. Niederseer, W. Patsch, D. Weghuber, J. Tevini, C. Datz, E. Aigner
Diabetes & Metabolism.2019; 45(2): 132. CrossRef Molecular pathways of nonalcoholic fatty liver disease development and progression
Fernando Bessone, María Valeria Razori, Marcelo G. Roma
Cellular and Molecular Life Sciences.2019; 76(1): 99. CrossRef Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir
David Sooik Kim, Mi Young Jeon, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Seung Up Kim
Clinical and Molecular Hepatology.2019; 25(3): 283. CrossRef Genetics Meets Therapy? Exome‐wide Association Study Reveals a Loss‐of‐Function Variant in 17‐Beta‐Hydroxysteroid Dehydrogenase 13 That Protects Patients From Liver Damage and Nonalcoholic Fatty Liver Disease Progression
Silvia Sookoian, Marco Arrese, Carlos J. Pirola
Hepatology.2019; 69(2): 907. CrossRef Homeostasis of Glucose and Lipid in Non-Alcoholic Fatty Liver Disease
Hsu-Wen Chao, Shi-Wei Chao, Heng Lin, Hui-Chen Ku, Ching-Feng Cheng
International Journal of Molecular Sciences.2019; 20(2): 298. CrossRef A Multifaceted Approach regarding the Association of the DsbA-L Gene with the Risk of Obesity-related Diseases Based on Clinical Pharmacogenetics
Kentaro Oniki, Junji Saruwatari
YAKUGAKU ZASSHI.2019; 139(1): 53. CrossRef Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease
Carlos J. Pirola, Martin Garaycoechea, Diego Flichman, Marco Arrese, Julio San Martino, Carla Gazzi, Gustavo O. Castaño, Silvia Sookoian
Journal of Lipid Research.2019; 60(1): 176. CrossRef Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease
Ki Tae Suk, Dong Joon Kim
Expert Review of Gastroenterology & Hepatology.2019; 13(3): 193. CrossRef An integrative systems genetic analysis of mammalian lipid metabolism
Benjamin L. Parker, Anna C. Calkin, Marcus M. Seldin, Michael F. Keating, Elizabeth J. Tarling, Pengyi Yang, Sarah C. Moody, Yingying Liu, Eser J. Zerenturk, Elise J. Needham, Matthew L. Miller, Bethan L. Clifford, Pauline Morand, Matthew J. Watt, Ruth C.
Nature.2019; 567(7747): 187. CrossRef Obesity genetics and cardiometabolic health: Potential for risk prediction
Dharambir K. Sanghera, Cynthia Bejar, Sonali Sharma, Rajeev Gupta, Piers R. Blackett
Diabetes, Obesity and Metabolism.2019; 21(5): 1088. CrossRef Combined effects of ambient particulate matter exposure and a high-fat diet on oxidative stress and steatohepatitis in mice
Shibin Ding, Chunyan Yuan, Bingjie Si, Mengruo Wang, Shuyan Da, Lanxin Bai, Weidong Wu, Qinghua Sun
PLOS ONE.2019; 14(3): e0214680. CrossRef Dysregulation of the Splicing Machinery Is Associated to the Development of Nonalcoholic Fatty Liver Disease
Mercedes del Río-Moreno, Emilia Alors-Pérez, Sandra González-Rubio, Gustavo Ferrín, Oscar Reyes, Manuel Rodríguez-Perálvarez, Marina E Sánchez-Frías, Rafael Sánchez-Sánchez, Sebastián Ventura, José López-Miranda, Rhonda D Kineman, Manuel de la Mata, Justo
The Journal of Clinical Endocrinology & Metabolism.2019; 104(8): 3389. CrossRef GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network
Bahram Namjou, Todd Lingren, Yongbo Huang, Sreeja Parameswaran, Beth L. Cobb, Ian B. Stanaway, John J. Connolly, Frank D. Mentch, Barbara Benoit, Xinnan Niu, Wei-Qi Wei, Robert J. Carroll, Jennifer A. Pacheco, Isaac T. W. Harley, Senad Divanovic, David S.
BMC Medicine.2019;[Epub] CrossRef TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population
Qun Liu, Shou-Sheng Liu, Zhen-Zhen Zhao, Ben-Tian Zhao, Shui-Xian Du, Wen-Wen Jin, Yong-Ning Xin
Lipids in Health and Disease.2019;[Epub] CrossRef Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient
Shahinul Alam, Mohammad Jahid Hasan, Md. Abdullah Saeed Khan, Mahabubul Alam, Nazmul Hasan
Journal of Translational Internal Medicine.2019; 7(3): 106. CrossRef Lifestyle and Food Habits Impact on Chronic Diseases: Roles of PPARs
Michele d’Angelo, Vanessa Castelli, Maria Grazia Tupone, Mariano Catanesi, Andrea Antonosante, Reyes Dominguez-Benot, Rodolfo Ippoliti, Anna Maria Cimini, Elisabetta Benedetti
International Journal of Molecular Sciences.2019; 20(21): 5422. CrossRef Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease
Blencowe, Karunanayake, Wier, Hsu, Yang
Genes.2019; 10(12): 966. CrossRef Non-alcoholic Fatty Liver Disease: Growing Burden, Adverse Outcomes and Associations
Ramesh Kumar, Rajeev Nayan Priyadarshi, Utpal Anand
Journal of Clinical and Translational Hepatology.2019; X(X): 1. CrossRef Systematic review with meta‐analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease
S. Sookoian, C. J. Pirola
Alimentary Pharmacology & Therapeutics.2018; 47(1): 16. CrossRef Sex differences between parental pregnancy characteristics and nonalcoholic fatty liver disease in adolescents
Oyekoya T. Ayonrinde, Leon A. Adams, Trevor A. Mori, Lawrence J. Beilin, Nicholas de Klerk, Craig E. Pennell, Scott White, John K Olynyk
Hepatology.2018; 67(1): 108. CrossRef Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease
Lindsey S Treviño, Tiffany A Katz
Endocrinology.2018; 159(1): 20. CrossRef Lean NAFLD: A not so benign condition?
Lisa B. VanWagner, Matthew J. Armstrong
Hepatology Communications.2018; 2(1): 5. CrossRef Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
Julia Wattacheril, Danny Issa, Arun Sanyal
Annual Review of Pharmacology and Toxicology.2018; 58(1): 649. CrossRef Evaluation of Polygenic Determinants of Non-Alcoholic Fatty Liver Disease (NAFLD) By a Candidate Genes Resequencing Strategy
Alessia Di Costanzo, Francesca Belardinilli, Diego Bailetti, Marialuisa Sponziello, Laura D’Erasmo, Licia Polimeni, Francesco Baratta, Daniele Pastori, Fabrizio Ceci, Anna Montali, Gabriella Girelli, Bruna De Masi, Antonio Angeloni, Giuseppe Giannini, Mar
Scientific Reports.2018;[Epub] CrossRef Combining Genetic Variants to Improve Risk Prediction for NAFLD and Its Progression to Cirrhosis: A Proof of Concept Study
Umberto Vespasiani-Gentilucci, Chiara Dell’Unto, Antonio De Vincentis, Andrea Baiocchini, Marco Delle Monache, Roberto Cecere, Adriano Maria Pellicelli, Valerio Giannelli, Simone Carotti, Giovanni Galati, Paolo Gallo, Francesco Valentini, Franca Del Nonno
Canadian Journal of Gastroenterology and Hepatology.2018; 2018: 1. CrossRef Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica
Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M
Gastroenterología y Hepatología.2018; 41(5): 328. CrossRef NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
Subada Soti, Kathleen E. Corey, Jordan E. Lake, Kristine M. Erlandson
Current HIV/AIDS Reports.2018; 15(3): 212. CrossRef Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity
Carlos J Pirola, Silvia Sookoian
World Journal of Gastroenterology.2018; 24(15): 1601. CrossRef The gut–liver axis and the intersection with the microbiome
Anupriya Tripathi, Justine Debelius, David A. Brenner, Michael Karin, Rohit Loomba, Bernd Schnabl, Rob Knight
Nature Reviews Gastroenterology & Hepatology.2018; 15(7): 397. CrossRef Nonalcoholic Steatohepatitis
Michael H. Schild, Cynthia D. Guy
Surgical Pathology Clinics.2018; 11(2): 267. CrossRef Dietary carbohydrates and fatty liver disease
Sally Chiu, Kathleen Mulligan, Jean-Marc Schwarz
Current Opinion in Clinical Nutrition & Metabolic Care.2018; 21(4): 277. CrossRef Consensus document. Management of non-alcoholic fatty liver disease (NAFLD). Clinical practice guideline
Rocío Aller, Conrado Fernández-Rodríguez, Oreste lo Iacono, Rafael Bañares, Javier Abad, José Antonio Carrión, Carmelo García-Monzón, Joan Caballería, Marina Berenguer, Manuel Rodríguez-Perálvarez, José López Miranda, Eduardo Vilar-Gómez, Javier Crespo, M
Gastroenterología y Hepatología (English Edition).2018; 41(5): 328. CrossRef Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126
Robin Mesnage, Martina Biserni, Sucharitha Balu, Clément Frainay, Nathalie Poupin, Fabien Jourdan, Eva Wozniak, Theodoros Xenakis, Charles A. Mein, Michael N. Antoniou
Archives of Toxicology.2018; 92(8): 2533. CrossRef Mechanisms of NAFLD development and therapeutic strategies
Scott L. Friedman, Brent A. Neuschwander-Tetri, Mary Rinella, Arun J. Sanyal
Nature Medicine.2018; 24(7): 908. CrossRef The Role of Long Non-Coding RNAs (lncRNAs) in the Development and Progression of Fibrosis Associated with Nonalcoholic Fatty Liver Disease (NAFLD)
Amanda Hanson, Danielle Wilhelmsen, Johanna DiStefano
Non-Coding RNA.2018; 4(3): 18. CrossRef Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis
Brett R Loman, Diego Hernández-Saavedra, Ruopeng An, R Scott Rector
Nutrition Reviews.2018; 76(11): 822. CrossRef Science, serendipity, and the single degree
Helen H. Hobbs
Journal of Clinical
Investigation.2018; 128(10): 4218. CrossRef Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics
Min Seok Cho, Sang Yeol Kim, Ki Tae Suk, Byung-Yong Kim
Journal of Microbiology.2018; 56(12): 855. CrossRef Promoting genetics in non-alcoholic fatty liver disease: Combined risk score through polymorphisms and clinical variables
Umberto Vespasiani-Gentilucci, Paolo Gallo, Chiara Dell’Unto, Mara Volpentesta, Raffaele Antonelli-Incalzi, Antonio Picardi
World Journal of Gastroenterology.2018; 24(43): 4835. CrossRef Nonalcoholic Fatty Liver Disease Progresses into Severe NASH when Physiological Mechanisms of Tissue Homeostasis Collapse
Silvia Sookoian, Carlos J. Pirola
Annals of Hepatology.2018; 17(2): 182. CrossRef Pediatric Non-Alcoholic Fatty Liver Disease
Haley Bush, Pegah Golabi, Zobair M. Younossi
Children.2017; 4(6): 48. CrossRef A Nutrigenomic Approach to Non-Alcoholic Fatty Liver Disease
Paola Dongiovanni, Luca Valenti
International Journal of Molecular Sciences.2017; 18(7): 1534. CrossRef Hígado graso no alcohólico: una pandemia poco conocida
Salvador Augustin, Isabel Graupera, Juan Caballeria
Medicina Clínica.2017; 149(12): 542. CrossRef Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
Giuseppe Della Pepa, Claudia Vetrani, Gianluca Lombardi, Lutgarda Bozzetto, Giovanni Annuzzi, Angela Rivellese
Nutrients.2017; 9(10): 1065. CrossRef What Is the Optimal Dietary Composition for NAFLD?
Elena S. George, Audrey C. Tierney, Katrina L. Campbell, Graeme A. Macdonald, Ingrid J. Hickman
Current Hepatology Reports.2017; 16(4): 346. CrossRef Non-alcoholic fatty liver disease: A poorly known pandemic
Salvador Augustin, Isabel Graupera, Juan Caballeria
Medicina Clínica (English Edition).2017; 149(12): 542. CrossRef
|